KIT and gastrointestinal stromal tumor: Previous reports have some shed light on alternate oncogenic drivers in this subset of so-called “wild-type” GIST that are more prevalent in young females and associated with multifocal but indolent disease, gastric primary, and lack of response to traditional KIT/PDGFRA TKIs such as imatinib [7].